Saving Your Sight: Standard of Care Treatment
At a Glance
AAION is an emergency caused by giant cell arteritis. High-dose steroids, often given through a vein first and then as prednisone pills, are started promptly to protect the other eye; vision already lost is usually permanent.
If your doctors suspect Arteritic Anterior Ischemic Optic Neuropathy (AAION), you will be started on high-dose medication immediately—often before any tests are even finished [1][2]. The goal of this rapid intervention is not necessarily to “fix” the vision that has already been lost, but to save the vision you have left [3][4].
The Acute Treatment Goal: Protection
The most critical thing to understand about AAION is that the vision loss from the initial event is usually permanent [5][1]. Because the optic nerve has been starved of blood and oxygen, the tissue is damaged, and while outcomes vary, the loss is usually severe and permanent [5].
However, Giant Cell Arteritis (GCA) is a body-wide disease. Without immediate treatment, there is a very high risk that ongoing GCA can cause ischemic injury in the other eye, often within just a few days [3][2]. High-dose steroids are used to “cool down” the inflamed arteries as quickly as possible to reduce this risk [2][6].
Standard “Pulse” Therapy
For vision-threatening cases, doctors often use a treatment called pulse therapy [1][4]. This typically involves:
- Intravenous (IV) Steroids: You may be admitted to the hospital to receive methylprednisolone (often 500 to 1,000 mg per day) through an IV for about 3 days [1][3].
- Transition to Oral Medication: After the IV pulses, you will be switched to high-dose oral prednisone (often 60 mg to 80 mg daily) [7][1].
While IV steroids are commonly considered for saving the second eye, high-dose oral steroids are also appropriate in some cases depending on the clinical situation and local protocol [5]. Even after treatment starts, the first 48 hours are the most critical; you must report any new visual “flickers” or dimming in either eye to your medical team instantly [3].
Steroid Safety Rules
Long-term steroid use helps control GCA, but requires strict safety habits:
- Medication Safety: Never stop abruptly or change your dose without medical advice. Stopping suddenly can cause adrenal crisis [8].
- Sick day rules: Ask your doctor what to do if you are vomiting and cannot take your pills.
Steroid-Sparing Treatments
Because the inflammation in GCA can last for months or even years, you may need to take steroids for a long time [8]. To avoid the side effects of long-term steroid use (such as bone thinning or high blood sugar), doctors often add steroid-sparing agents [9][10].
- Tocilizumab (Actemra): This is a modern biological medication that blocks the IL-6 receptor pathway [9]. In major clinical trials, patients taking tocilizumab were much more likely to stay in remission and were able to take significantly lower total doses of steroids [9]. It requires careful screening and monitoring for infection, blood counts, and liver abnormalities, and can make CRP or fever less reliable.
- Methotrexate: This is an older, well-studied medication that can also help reduce the amount of steroids you need [10]. It is often used if tocilizumab is not an option for you [12].
Why Immediate Action Matters
Every hour counts. In a study of patients who lost vision in their first eye, the median time for the second eye to be affected was only 2 days [3]. This is why your medical team will move with such urgency [6]. Starting treatment at the first sign of clinical suspicion—even if the biopsy hasn’t happened yet—is the standard of care to protect your remaining sight [1][2].
Common questions in this guide
Can treatment restore vision that AAION has already taken away?
Why are steroids started before my test or biopsy results are complete?
What does pulse steroid treatment for AAION involve?
Can tocilizumab replace emergency steroids for AAION?
What should I do if my other eye starts flickering or dimming?
Why should I avoid stopping prednisone suddenly?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my vision loss, should I be receiving intravenous 'pulse' steroids in the hospital, and for how many days?
- 2.What is the plan to transition from IV steroids to oral medication, and how high will my oral dose be?
- 3.Since steroids can cause side effects like high blood sugar or bone loss, what is your plan for monitoring and protecting me during long-term treatment?
- 4.When can we discuss adding a steroid-sparing agent like tocilizumab to help reduce my total steroid dose?
- 5.If I notice any new flickering or dimming in my other eye tonight, how exactly should I contact the team?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Giant Cell Arteritis: Updates and Controversies.
Yu E, Chang JR
Frontiers in ophthalmology 2022; (2()):848861 doi:10.3389/fopht.2022.848861.
PMID: 38983551 - 2
Giant Cell Arteritis.
Ness T, Nölle B
Klinische Monatsblatter fur Augenheilkunde 2024; (241(5)):644-652 doi:10.1055/a-2252-3371.
PMID: 38593832 - 3
Vision loss in giant cell arteritis: case-based review.
Kokloni IN, Aligianni SI, Makri O, Daoussis D
Rheumatology international 2022; (42(10)):1855-1862 doi:10.1007/s00296-022-05160-x.
PMID: 35727336 - 4
Giant cell arteritis: a closer look at its ophthalmological manifestations.
Pinto Ferreira NG, Menezes Falcão L, Alves AT, Campos F
BMJ case reports 2015; (2015()).
PMID: 26416775 - 5
Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study.
Dumont A, Lecannuet A, Boutemy J, et al.
Seminars in arthritis and rheumatism 2020; (50(2)):335-341 doi:10.1016/j.semarthrit.2019.09.008.
PMID: 32192630 - 6
Biopsy vs imaging in the diagnosis of giant cell arteritis. Viewpoint 1: in favour of imaging.
Schmidt WA
Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i71-i73 doi:10.1093/rheumatology/keae487.
PMID: 40071427 - 7
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Hellmich B, Agueda A, Monti S, et al.
Annals of the rheumatic diseases 2020; (79(1)):19-30 doi:10.1136/annrheumdis-2019-215672.
PMID: 31270110 - 8
Neuro-ophthalmic Manifestations of Giant Cell Arteritis: A Review.
Khoury JA, Albreiki D
Journal of ophthalmic & vision research 2025; (20()) doi:10.18502/jovr.v20.15248.
PMID: 40689118 - 9
Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH, Tuckwell K, Dimonaco S, et al.
The New England journal of medicine 2017; (377(4)):317-328 doi:10.1056/NEJMoa1613849.
PMID: 28745999 - 10
Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements.
Dammacco R, Alessio G, Giancipoli E, et al.
Clinical ophthalmology (Auckland, N.Z.) 2020; (14()):775-793 doi:10.2147/OPTH.S243203.
PMID: 32210531 - 11
Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.
Christ L, Seitz L, Scholz G, et al.
The Lancet. Rheumatology 2021; (3(9)):e619-e626 doi:10.1016/S2665-9913(21)00152-1.
PMID: 38287611 - 12
Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies.
Badla O, Badla BA, Almobayed A, et al.
Pharmaceuticals (Basel, Switzerland) 2024; (17(10)) doi:10.3390/ph17101281.
PMID: 39458922
This page explains emergency AAION treatment for education and does not replace medical advice. Contact your ophthalmology or rheumatology team urgently about vision changes, steroid doses, and treatment decisions.
Get notified when new evidence is published on arteritic anterior ischemic optic neuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.